Melissa E Elder, M.D., Ph.D.
Professor & Chief
Teaching Profile
Courses Taught
2013
MDT7400 Elect Top/Pediatrics
2010-2013
MEL7937 Elect Top/Pediatrics
Board Certifications
-
Pediatric RheumatologyAmerican Board of Pediatrics
-
PediatricsAmerican Board of Pediatrics
Clinical Profile
Specialties
- Pediatrics
Subspecialties
- Immunology
- Pediatric Rheumatology
Areas of Interest
- Angioedema
- Atopic dermatitis
- Autoimmune disorders
- Dermatomyositis
- Granulomatosis with polyangiitis
- Immunodeficiency disorders
- Juvenile idiopathic arthritis
- Osteomyelitis in children
- Polyarteritis nodosa
- Rheumatoid arthritis
- Sarcoidosis
- Scleroderma
- Selective deficiency of IgA
- Systemic lupus erythematosus
- Takayasu arteritis
- Uveitis
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-8820-5515
Publications
2024
Case Report: Hypocomplementemic urticarial vasculitis syndrome in a pediatric patient with complement factor 1 deficiency.
Frontiers in pediatrics.
12
[DOI] 10.3389/fped.2024.1448094.
[PMID] 39376673.
2024
Chronic Recurrent Multifocal Osteomyelitis Involving the Spine, Sternum, and Lower Extremities: A Case Report.
Pediatrics.
154(4)
[DOI] 10.1542/peds.2024-067527.
[PMID] 39323407.
2024
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset ANCA-Associated Vasculitis: An ARChiVe registry-cohort study.
Arthritis care & research.
[DOI] 10.1002/acr.25455.
[PMID] 39467015.
2024
Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies.
The Journal of clinical investigation.
134(1)
[DOI] 10.1172/JCI173510.
[PMID] 37988172.
2023
Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation.
Molecular therapy. Methods & clinical development.
30:303-314
[DOI] 10.1016/j.omtm.2023.06.001.
[PMID] 37601414.
2023
Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases.
Clinical rheumatology.
42(7):1965-1979
[DOI] 10.1007/s10067-023-06559-y.
[PMID] 36971919.
2023
Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia.
Frontiers in pediatrics.
11
[DOI] 10.3389/fped.2023.1336554.
[PMID] 38322244.
2023
Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus.
Clinical and experimental rheumatology.
41(1):186-194
[DOI] 10.55563/clinexprheumatol/tn0x4k.
[PMID] 36135940.
2022
Secondary hemophagocytic lymphohistiocytosis following Zolgensma therapy: An evolving story on the innate response to systemic gene therapy.
Molecular therapy : the journal of the American Society of Gene Therapy.
30(12):3503-3504
[DOI] 10.1016/j.ymthe.2022.11.007.
[PMID] 36436512.
2021
Takayasu’s arteritis presenting as acute myocardial infarction: case series and review of literature.
Cardiology in the young.
31(11):1866-1869
[DOI] 10.1017/S1047951121001700.
[PMID] 34016208.
2021
The Diagnostic Performance of Early Sjögren’s Syndrome Autoantibodies in Juvenile Sjögren’s Syndrome: The University of Florida Pediatric Cohort Study.
Frontiers in immunology.
12
[DOI] 10.3389/fimmu.2021.704193.
[PMID] 34249010.
2020
Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Pediatric neurology.
111:40-43
[DOI] 10.1016/j.pediatrneurol.2020.07.002.
[PMID] 32951658.
2020
The first case of monozygotic twin boys with nearly identical features of Sjögren’s syndrome.
Rheumatology (Oxford, England).
59(3):687-688
[DOI] 10.1093/rheumatology/kez428.
[PMID] 31566227.
2019
A Novel Manifestation of Prolidase Deficiency in a Toddler Diagnosed With Very-early-onset Crohn Disease
Journal of Pediatric Gastroenterology and Nutrition.
69(3):E89-E90
[DOI] 10.1097/MPG.0000000000002402.
2019
Anakinra as an agent to control hemophagocytic lymphohistiocytosis in Griscelli type 2.
Pediatric blood & cancer.
66(12)
[DOI] 10.1002/pbc.27997.
[PMID] 31535456.
2019
End-stage renal disease secondary to anti-glomerular basement membrane disease in a child with common variable immunodeficiency.
Clinical nephrology. Case studies.
7:1-6
[DOI] 10.5414/CNCS109510.
[PMID] 30838168.
2019
Heterozygous FOXN1 Variants Cause Low TRECs and Severe T Cell Lymphopenia, Revealing a Crucial Role of FOXN1 in Supporting Early Thymopoiesis.
American journal of human genetics.
105(3):549-561
[DOI] 10.1016/j.ajhg.2019.07.014.
[PMID] 31447097.
2019
Overlapping dermatologic diagnoses in severe Crohn’s disease with duel genetic mutations.
International journal of dermatology.
58(11):e214-e216
[DOI] 10.1111/ijd.14520.
[PMID] 31209857.
2017
BK viruria and viremia in children with systemic lupus erythematosus.
Pediatric rheumatology online journal.
15(1)
[DOI] 10.1186/s12969-017-0156-2.
[PMID] 28399927.
2017
Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Arthritis & rheumatology (Hoboken, N.J.).
69(7):1470-1479
[DOI] 10.1002/art.40112.
[PMID] 28371513.
2016
Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener’s): An ARChiVe Cohort Study.
Arthritis & rheumatology (Hoboken, N.J.).
68(10):2514-26
[DOI] 10.1002/art.39729.
[PMID] 27111558.
2016
The family journey-to-diagnosis with systemic juvenile idiopathic arthritis: a cross-sectional study of the changing social media presence.
Open access rheumatology : research and reviews.
8:61-71
[PMID] 27843371.
2014
B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study.
Molecular therapy. Methods & clinical development.
1
[PMID] 25541616.
2014
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.
Arthritis & rheumatology (Hoboken, N.J.).
66(9):2570-9
[DOI] 10.1002/art.38699.
[PMID] 24839206.
2014
Tocilizumab in the Treatment of Refractory Uveitis in Children
Annals of the Rheumatic Diseases.
73(2):588-589
[DOI] 10.1136/annrheumdis-2014-eular.3773.
2013
B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.
The Journal of pediatrics.
163(3):847-54.e1
[DOI] 10.1016/j.jpeds.2013.03.002.
[PMID] 23601496.
2013
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Arthritis and Rheumatism.
65:S757-S758
2012
Acute-onset opioid-induced hyperalgesia in a child with juvenile idiopathic arthritis.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
18(7):349-51
[DOI] 10.1097/RHU.0b013e31826d2663.
[PMID] 23047535.
2012
Macrophage activation syndrome, an important differential diagnosis for septic shock.
Journal of pediatric intensive care.
1(4):211-216
[DOI] 10.3233/PIC-12035.
[PMID] 31214411.
2012
Takayasu’s arteritis: Is it a reversible disease? Case Report and Literature Review.
Surgical neurology international.
3
[DOI] 10.4103/2152-7806.102947.
[PMID] 23227437.
2011
Immune Modulation in Early Onset Pompe Disease
Molecular Genetics and Metabolism.
102(2):S31-S32
[DOI] 10.1016/j.ymgme.2010.11.107.
2011
Pompe disease gene therapy.
Human molecular genetics.
20(R1):R61-8
[DOI] 10.1093/hmg/ddr174.
[PMID] 21518733.
2011
Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Human gene therapy.
22(8):935-49
[DOI] 10.1089/hum.2010.121.
[PMID] 21142972.
2007
Detection of single clone deletions using array CGH: identification of submicroscopic deletions in the 22q11.2 deletion syndrome as a model system.
American journal of medical genetics. Part A.
143A(9):925-32
[PMID] 17394204.
2005
Association between beta2-glycoprotein I gene polymorphisms and pediatric SLE and antiphospholipid antibodies.
Lupus.
14(6):440-4
[PMID] 16038107.
2003
Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates.
Nature medicine.
9(4):463-8
[PMID] 12640448.
2003
Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis.
The Journal of infectious diseases.
188(12):1845-52
[PMID] 14673763.
2003
Thrombosis and pediatric Wegener’s granulomatosis: acquired and genetic risk factors for hypercoagulability.
Arthritis and rheumatism.
49(6):862-5
[PMID] 14673976.
2002
Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
Arthritis and rheumatism.
47(4):414-20
[PMID] 12209489.
2001
Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70.
Journal of immunology (Baltimore, Md. : 1950).
166(1):656-61
[PMID] 11123350.
2000
A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).
American journal of human genetics.
67(6):1555-62
[PMID] 11047757.
2000
T-cell immunodeficiencies.
Pediatric clinics of North America.
47(6):1253-74
[PMID] 11130995.
1999
Cytokine profile of a long-term pediatric HIV survivor with hyper-IgE syndrome and a normal CD4 T-cell count.
The Journal of allergy and clinical immunology.
104(5):1045-51
[PMID] 10550751.
1998
ZAP-70 and defects of T-cell receptor signaling.
Seminars in hematology.
35(4):310-20
[PMID] 9801260.
1996
Severe combined immunodeficiency due to a defect in the tyrosine kinase ZAP-70.
Pediatric research.
39(5):743-8
[PMID] 8726223.
1995
Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency.
Cellular immunology.
165(1):110-7
[PMID] 7671314.
1994
ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency.
Science (New York, N.Y.).
264(5165):1599-601
[PMID] 8202713.
1988
Thymosin and the spontaneously diabetic BB rat.
Autoimmunity.
1(2):115-23
[PMID] 2979610.
1983
Autoimmune diatheses and T lymphocyte immunoincompetences in BB rats.
Metabolism: clinical and experimental.
32(7 Suppl 1):92-6
[PMID] 6345999.
1983
Identification of profound peripheral T lymphocyte immunodeficiencies in the spontaneously diabetic BB rat.
Journal of immunology (Baltimore, Md. : 1950).
130(4):1723-31
[PMID] 6220066.
Grants
Aug 2023
ACTIVE
USIDNET: A resource for clinical immunologists
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH
Jan 2023
ACTIVE
AN OPEN LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY AND SAFETY OF ASCENIV (IGIV) IN PEDIATRIC SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
Role: Principal Investigator
Funding: ATLANTIC RESEARCH GROUP
via ADMA BIOLOGICS
Aug 2022
ACTIVE
A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Stills disease (including systemic juvenile idiopathic arthritis and Adult onset Stills disease) or with MAS in Systemic lupus erythematous
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via SWEDISH ORPHAN BIOVITRUM AB
Apr 2022
ACTIVE
Chronic childhood vasculitis: Characterizing the individual rare diseases to improve patient outcomes (Pediatric Vasculitis Initiative or PedVas)
Role: Principal Investigator
Funding: UNIV OF BRITISH COLUMBIA
Feb 2021
– Aug 2023
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
Role: Principal Investigator
Funding: SANOFI US SERVICES
Jul 2020
– Jun 2024
University of Florida Pediatric Rheumatology Fellowship Program
Role: Principal Investigator
Funding: ARTHRITIS FOU
Feb 2020
ACTIVE
An Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept (Orencia) in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Role: Principal Investigator
Funding: DUKE UNIVERSITY
via PATIENT-CENTERED OUTCOMES RES INST
Mar 2019
– Mar 2020
A Registry of Patients with Primary Immunodeficiency Disorders
Role: Principal Investigator
Funding: US IMMUNODEFICIENCY NETWORK (USIDNET)
via NATL INST OF HLTH NIAID
Jul 2016
ACTIVE
CMS Newborn Screening – COQWX
Role: Principal Investigator
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS
Jan 2013
– Mar 2022
Chronic childhood vasculitis: Characterizing the individual rare diseases to improve patient outcomes
Role: Principal Investigator
Funding: UNIV OF BRITISH COLUMBIA
via CANADIAN INST OF HLTH RES
May 2012
ACTIVE
CLINICAL TRIAL OPERATING ACCOUNT
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jan 2011
– Jun 2016
Genetics/Newborn/Cystic Fibrosis Screening
Role: Project Manager
Funding: FL DEPT OF HLTH
Education
Fellowship – Pediatric Rheumatology
1992
·
University of California – San Francisco
Residency – Pediatrics
1989
·
Johns Hopkins Hospital
Medical School
1986
·
University of Florida
Ph.D – Microbiology & Immunology
1982
·
University of Florida
Contact Details
Phones:
- Business:
- (352) 294-5252
Emails:
- Business:
- elderme@peds.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100296
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610